NervGen Pharma Responds to Recent Increase in Market Activity
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, confirms that the Company's management is unaware of any undisclosed information or material change in the Company's operations that would account for the recent increase in market activity. About NervGen NervGen is restoring life's...
2020-01-13 10:53 AM EST
NervGen Pharma Appoints Paul Brennan as President & Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - November 27, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. Paul Brennan to the position of President & CEO effective immediately, replacing Dr. Ernest Wong who will continue to formally support the Company as a consultant. Mr. Brennan has also been appointed...
2019-11-27 8:00 AM EST
NervGen Pharma Completes Share Issuance to Drug Manufacturing Partner CSBio
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that, further to its press release dated November 18, 2019, it has issued 1,500,000 common shares (the "Common Share(s)") to its manufacturing partner, CSBio, as partial consideration for an order of NVG-291 that will be...
2019-11-21 8:30 AM EST
NervGen Pharma Receives Investment from Drug Manufacturing Partner
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has entered into an agreement to issue 1,500,000 common shares at a price of US$1.00 (CA$1.3231 equivalent) per common share on a private placement basis for a deemed value of US$1,500,000 with its peptide...
2019-11-18 8:30 AM EST
NervGen Pharma Expands Platform into Alzheimer's Disease
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating novel treatments for nerve damage and neurodegenerative diseases, today announced a research initiative to advance its proprietary therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis, to generate new treatments for Alzheimer's disease ("AD")....
2019-10-28 8:30 AM EDT
NervGen Pharma Announces Clinical Development Plan for the Treatment of Nerve Damage and Neurodegenerative Diseases
Vancouver, British Columbia--(Newsfile Corp. - September 6, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the clinical development strategy for its compound, NVG-291, in two lead indications: spinal cord injury and multiple sclerosis. The NVG-291 clinical development program is planned as follows:...
2019-09-06 8:30 AM EDT
NervGen Pharma's Multiple Sclerosis Development Program Targeting Nerve Remylenation Supported by Publication of Independent Peer Reviewed Paper
Vancouver, British Columbia--(Newsfile Corp. - July 10, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reports the publication of a new, independent study using NervGen's core Intracellular Sigma Peptide ("ISP") technology in a mouse model representative of demyelination in multiple sclerosis. The peer...
2019-07-10 9:00 AM EDT
NervGen Amends Investor Relations Agreement
Vancouver, British Columbia--(Newsfile Corp. - July 5, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the Company has agreed to amend the terms of an investor relations services agreement dated January 16, 2019 with Mr. Huitt Tracey of Vancouver, Canada. Mr. Tracey is being granted an additional...
2019-07-05 5:00 PM EDT
NervGen Pharma Launches Multiple Sclerosis Program Targeting Nerve Remyelination
Vancouver, British Columbia--(Newsfile Corp. - June 26, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced its goal to apply its proprietary platform drug technology beyond spinal cord injury to multiple sclerosis ("MS"), another debilitating nerve damage related condition impacting millions of patients...
2019-06-26 9:00 AM EDT
NervGen Pharma Announces Upgrade to the OTCQX Best Market in the U.S.
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has qualified to trade its common shares on the OTCQX® Best Market ("OTCQX"). NervGen upgraded to OTCQX from the OTCQB® Venture Market and begins trading today under the symbol...
2019-06-10 7:00 AM EDT
NervGen Pharma Presenting at the 9th Annual LD Micro Invitational
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that Ernest Wong, NervGen Pharma's President & CEO, will be presenting at the 9th Annual LD Micro Invitational on Wednesday, June 5 at 8:40AM PDT / 11:40AM EDT. In addition,...
2019-06-04 3:30 PM EDT
NervGen Pharma Engages Torrey Hills Capital for Investor Relations
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has engaged San Diego based Torrey Hills Capital, Inc. ("Torrey Hills Capital") to provide market awareness and investor relations services to the Company. Torrey Hills...
2019-06-03 8:30 AM EDT
NervGen Pharma Appoints Dr. Denis Bosc as Vice President of Manufacturing
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has appointed Denis Bosc, PhD, as the Company's Vice President, Chemistry, Manufacturing and Control (CMC). In addition, Paul Brennan has joined the NervGen team to...
2019-05-30 9:00 AM EDT
NervGen Pharma Commences Trading on OTCQB
Vancouver, British Columbia--(Newsfile Corp. - May 3, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage including spinal cord and peripheral nerve injury, today announced that in addition to trading on the TSX Venture Exchange, its common shares will commence trading today on the OTCQB Venture Market under the symbol "NGENF". "The commencement of...
2019-05-03 9:00 AM EDT
NervGen Pharma to Ring the Opening Bell of Toronto Stock Exchange
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2019) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage including spinal cord and peripheral nerve injury, today announced that the Company will ring the opening bell at Toronto Stock Exchange tomorrow morning to celebrate its listing on March 13, 2019. "As the Company continues to broaden its support in the...
2019-05-01 2:26 PM EDT
NervGen Pharma's Patent Estate Grows with the Addition of US Patents for Its Groundbreaking Nerve Regeneration Technology
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2019) - NervGen Pharma Corp. ("NervGen"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, announces the issuance by the U.S. Patent and Trademark Office of two new patents protecting the development and commercialization of protein tyrosine phosphatase sigma (PTPσ
2019-04-24 9:00 AM EDT
Amended: NervGen Pharma Increases Private Placement to $740,000
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2019) - NervGen Pharma Corp. ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has increased the amount of its non-brokered private placement announced on March 14, 2019 from $500,000 to $740,000. The Company now intends to issue 350,000 shares at $1.00 each (as before) and 300,000 shares at $1.30 each (new). The net...
2019-04-23 6:08 PM EDT
NervGen Pharma Increases Private Placement to $650,000
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2019) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has increased the amount of its non-brokered private placement announced on March 14, 2019 from $500,000 to $650,000. The Company now intends to issue 350,000 shares at $1.00 each (as before) and 300,000 shares at $1.30 each (new)....
2019-04-22 4:02 PM EDT
NervGen Pharma Appoints Amy Franke as VP, Clinical Operations
Vancouver, British Columbia--(Newsfile Corp. - April 1, 2019) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Amy Franke as the Company's Vice President, Clinical Operations. "With the recent successful completion of our Initial Public Offering, we are fully focused on driving our lead drug candidate, NVG-291, into clinical...
2019-04-01 8:30 AM EDT
NervGen Pharma Completes $10 Million Initial Public Offering; Shares to Commence Trading on TSX-V on March 15, 2019 - Symbol "NGEN"
Vancouver, British Columbia--(Newsfile Corp. - March 13, 2019) - NervGen Pharma Corp. ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has completed its initial public offering ("IPO") of its common shares and listing as a Tier 2 company on the TSX Venture Exchange ("TSX-V"). The IPO consisted of the issuance of 10,000,000 common shares of the Company at a price of $1.00 per...
2019-03-13 3:52 PM EDT